Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
Standard
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. / Sarrazin, Christoph; Schwendy, Susanne; Möller, Bernd; Dikopoulos, Nektarios; Buggisch, Peter; Encke, Jens; Teuber, Gerlinde; Goeser, Tobias; Thimme, Robert; Klinker, Hartwig; Boecher, Wulf O; Schulte-Frohlinde, Ewert; Prinzing, Renate; Herrmann, Eva; Zeuzem, Stefan; Berg, Thomas.
in: GASTROENTEROLOGY, Jahrgang 141, Nr. 5, 5, 2011, S. 1656-1664.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
AU - Sarrazin, Christoph
AU - Schwendy, Susanne
AU - Möller, Bernd
AU - Dikopoulos, Nektarios
AU - Buggisch, Peter
AU - Encke, Jens
AU - Teuber, Gerlinde
AU - Goeser, Tobias
AU - Thimme, Robert
AU - Klinker, Hartwig
AU - Boecher, Wulf O
AU - Schulte-Frohlinde, Ewert
AU - Prinzing, Renate
AU - Herrmann, Eva
AU - Zeuzem, Stefan
AU - Berg, Thomas
PY - 2011
Y1 - 2011
N2 - Guidelines recommend that patients with chronic hepatitis C virus (HCV) infection be treated with pegylated interferon and ribavirin for 24, 48, or 72 weeks, based on their virologic response to treatment. We investigated the effects of treating patients for individualized durations.
AB - Guidelines recommend that patients with chronic hepatitis C virus (HCV) infection be treated with pegylated interferon and ribavirin for 24, 48, or 72 weeks, based on their virologic response to treatment. We investigated the effects of treating patients for individualized durations.
KW - Adult
KW - Germany
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Adolescent
KW - Young Adult
KW - Treatment Outcome
KW - Time Factors
KW - Genotype
KW - Dose-Response Relationship, Drug
KW - Drug Therapy, Combination
KW - Antiviral Agents/therapeutic use
KW - Individualized Medicine/methods
KW - Ribavirin/adverse effects/therapeutic use
KW - Recombinant Proteins/adverse effects/therapeutic use
KW - RNA, Viral/blood
KW - Hepacivirus/genetics
KW - Hepatitis C, Chronic/drug therapy
KW - Interferon-alpha/adverse effects/therapeutic use
KW - Polyethylene Glycols/adverse effects/therapeutic use
KW - Adult
KW - Germany
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Adolescent
KW - Young Adult
KW - Treatment Outcome
KW - Time Factors
KW - Genotype
KW - Dose-Response Relationship, Drug
KW - Drug Therapy, Combination
KW - Antiviral Agents/therapeutic use
KW - Individualized Medicine/methods
KW - Ribavirin/adverse effects/therapeutic use
KW - Recombinant Proteins/adverse effects/therapeutic use
KW - RNA, Viral/blood
KW - Hepacivirus/genetics
KW - Hepatitis C, Chronic/drug therapy
KW - Interferon-alpha/adverse effects/therapeutic use
KW - Polyethylene Glycols/adverse effects/therapeutic use
M3 - SCORING: Journal article
VL - 141
SP - 1656
EP - 1664
JO - GASTROENTEROLOGY
JF - GASTROENTEROLOGY
SN - 0016-5085
IS - 5
M1 - 5
ER -
